Pacific Biosciences of California, Inc.

PACB Healthcare Medical Devices

Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.73 0.23 −11.73%
Market cap
$609.2M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
3/9
Altman Z
−6.04
Beneish M
−5.14
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 216.17 0.00 0.00 0.00 0.00
Piotroski F-Score
3 2 3 2 3 6 4 4 3 2
P/S ratio
3.51 3.26 12.13 13.90 32.00 54.31 8.63 12.71 3.15 4.28
Altman Z-Score
(6.04) (2.70) (0.12) (0.40) 1.55 29.53 (6.40) 1.84 (6.46) (4.57)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 232.07 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(13.42) (5.15) (1.59) (1.32) 1.36 (0.35) (26.02) (16.62) (19.21) (16.84)
Beneish M-Score
(5.14) (3.16) (1.48) (2.83) (1.00) (2.35) 0.72 (3.79) (3.18) (1.38)
P/Operating CF
(29.42) (16.39) (42.26) (29.44) (131.72) (300.42) (43.12) (52.66) (14.60) (30.13)
P/B ratio
104.86 0.99 3.47 3.17 5.28 12.77 14.28 8.76 3.42 4.59
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 12.77 14.28 8.76 3.42 4.59
EV/Sales
5.79 4.93 13.43 14.86 30.86 50.74 8.54 11.60 2.63 3.67
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(8.33) (3.68) (10.39) (7.25) (36.23) 205.27 (9.92) (13.73) (3.64) (4.90)
EV/FCF
(7.79) (3.58) (10.05) (6.81) (34.39) 216.82 (9.57) (13.36) (3.15) (4.37)
Quick Ratio
4.32 6.31 7.03 3.01 14.91 8.74 1.32 4.13 2.66 2.47
Current Ratio
5.15 7.48 7.81 3.24 15.36 9.24 1.65 4.90 3.55 3.23
Net Debt/EBITDA
(2.33) (1.03) (0.81) (0.43) 0.76 2.96 0.08 0.94 0.61 0.84
Debt/Assets
82.31% 51.37% 51.10% 50.74% 44.65% 9.18% 28.38% 8.61% 9.46% 11.68%
Debt/Equity
120.65 1.28 1.27 1.59 1.13 0.11 0.76 0.13 0.16 0.19
Asset Turnover
0.16 0.10 0.11 0.07 0.11 0.28 0.57 0.50 0.66 0.67
Operating CF/Net income
0.20 0.67 0.84 0.84 0.61 0.66 0.93 0.65 0.73 0.91
Capex/Depreciation
(0.02) (0.03) (0.65) (0.99) (0.38) (0.11) (0.28) (0.25) (1.08) (1.63)
Interest Coverage
(79.65) (35.36) (23.32) (20.91) (16.79) (390.96) (38.51) (41.68) (30.74) (22.03)
ROE
(213.45%) (51.30%) (48.53%) (46.42%) (32.18%) 15.06% (99.58%) (102.48%) (107.97%) (94.02%)
ROA
(53.45%) (20.61%) (17.46%) (16.65%) (14.97%) 10.46% (52.87%) (65.25%) (65.39%) (55.30%)
ROIC
(93.25%) (38.83%) (21.73%) (27.95%) (20.48%) (121.17%) (132.25%) (239.39%) (152.21%) (154.63%)
Return on Tangible Assets
(167.41%) (67.38%) (44.88%) (49.86%) (17.07%) 8.60% (135.78%) (73.87%) (83.13%) (82.83%)
Average Days of Receivables
80.86 65.23 66.65 53.44 67.79 77.90 61.31 39.90 52.46 45.95
Research and Development Expense of Revenue
60.81% 87.60% 93.34% 150.42% 86.50% 81.32% 65.61% 79.61% 69.89% 74.54%
Selling, General and Administrative Expense of Revenue
88.43% 113.64% 84.69% 125.37% 95.10% 92.28% 83.06% 80.75% 63.25% 52.68%
Intangible Assets out of Total Assets
0.42 0.56 0.53 0.46 0.41 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
26.04% 46.12% 35.97% 61.27% 56.21% 22.22% 18.04% 29.45% 21.77% 21.56%
Graham Net Nets
(0.72) (0.51) (0.12) (0.20) (0.03) 0.06 (0.02) 0.08 0.15 0.14
Graham Number
0.00 0.00 0.00 0.00 0.00 2.34 0.00 0.00 0.00 0.00
Earnings Yield
(98.40%) (62.30%) (12.62%) (17.63%) (4.35%) 0.46% (10.70%) (10.41%) (31.90%) (19.27%)
Free Cash Flow Yield
(21.20%) (42.25%) (11.02%) (15.70%) (2.80%) 0.43% (10.35%) (6.83%) (26.42%) (19.59%)
Revenue per Share
0.53 0.56 0.79 0.57 0.64 0.48 0.60 0.58 0.88 1.02
Operating CF per Share
(0.37) (0.75) (1.02) (1.17) (0.54) 0.12 (0.51) (0.49) (0.64) (0.76)
Capex per Share
(0.03) (0.02) (0.03) (0.08) (0.03) (0.01) (0.02) (0.01) (0.10) (0.09)
Free Cash Flow per Share
(0.40) (0.77) (1.06) (1.25) (0.57) 0.11 (0.53) (0.51) (0.74) (0.85)
Cash per Share
0.93 1.42 2.49 3.44 5.12 1.94 0.32 0.76 0.59 0.81
Shareholders Equity per Share
0.02 1.85 2.77 2.51 3.87 2.03 0.36 0.84 0.81 0.95
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.02 1.85 2.77 2.51 3.87 2.03 0.36 0.84 0.81 0.95
Free Cash Flow
(118.92) (212.25) (268.02) (280.14) (117.11) 18.46 (81.15) (68.28) (77.91) (76.13)
Working Capital
302.22 429.38 647.02 588.74 1,029.43 317.09 31.89 104.78 72.98 75.24
Capital Expenditures
(7.71) (6.19) (8.84) (16.93) (5.93) (1.04) (2.84) (1.85) (10.39) (8.20)
Net Current Asset Value
(403.68) (258.17) (302.66) (352.11) (114.85) 277.10 (12.02) 75.45 43.64 55.80
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.05 0.04 0.04 0.13 0.05 0.01 0.03 0.02 0.11 0.09
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
16.44 7.37 0.38 0.41 0.48 0.37 0.34 0.22 0.25 0.35
Cash ROIC
(12.78%) (13.74%) (12.04%) (12.55%) (4.29%) 2.66% (55.46%) (29.55%) (47.91%) (44.07%)
Accounts Receivable Turnover
5.08 4.80 7.24 5.96 6.35 4.92 7.62 7.14 7.52 10.89
Accounts Payable Turnover
6.11 7.38 10.91 6.88 9.83 7.76 7.46 6.76 6.74 7.10
Inventory Turnover
2.11 2.02 2.76 2.11 3.69 3.36 3.61 2.61 3.04 3.50
Average Days of Payables
66.37 51.87 37.21 55.38 56.04 28.20 54.24 45.93 56.44 65.54
Days of Inventory on Hand
157.49 183.72 140.02 231.98 125.31 112.12 86.28 121.90 143.15 122.58
Average Receivables
31.49 32.07 27.70 21.51 20.54 16.05 11.93 11.01 12.43 8.33
Average Payables
18.68 15.83 13.55 11.52 7.29 5.97 7.55 7.91 8.73 6.55
Average Inventory
54.02 57.72 53.53 37.49 19.41 13.77 15.60 20.47 19.35 13.29
Average Assets
1,022.27 1,503.23 1,756.55 1,887.03 1,210.48 280.98 159.13 157.18 140.98 134.50
Average Common Equity
255.97 603.95 632.10 676.95 563.24 195.20 84.49 100.08 85.39 79.10

Fold the line items

Columns are period end dates